Your shopping cart is currently empty

Lith-O-Asp is a sialytransferase (ST) inhibitor with IC50 values ranging from 12 to 37 μM.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $523 | 6-8 weeks | 6-8 weeks | |
| 25 mg | $1,520 | 6-8 weeks | 6-8 weeks | |
| 50 mg | $1,980 | 6-8 weeks | 6-8 weeks | |
| 100 mg | $2,500 | 6-8 weeks | 6-8 weeks |
| Description | Lith-O-Asp is a sialytransferase (ST) inhibitor with IC50 values ranging from 12 to 37 μM. |
| Targets&IC50 | ST:12-37 μM |
| In vitro | The results indicate that Lith-O-Asp reduces the activity of both a-2,3- and a-2,6-sialyltransferases, consequently inhibiting the transfer of sialic acids to target glycoproteins[1]. Despite showing no significant growth inhibition effect on various cancer cell lines at doses of 10, 30, and 60 μM, in vitro assays reveal Lith-O-Asp's capability to suppress the activities of ST3Gal I, ST3Gal III, and ST6GalI, with IC50 values ranging from 12 to 37 μM. Furthermore, flow cytometry analysis demonstrates a marked decrease in the expression of cell surface a-2,3- and a-2,6-sialylated antigens. |
| In vivo | In lung tissues of mice treated with DMSO and observed using the IVIS in vivo imaging system, a significant presence of secondary metastatic cancer cells was noted 26 days post-fat pad inoculation. Conversely, mice treated with Lith-O-Asp exhibited a reduction in lung metastases, with only 3 of 8 mice showing any metastasis compared to all DMSO-treated mice. The average number of tumor nodules per mouse in the DMSO group was 11±9, while in the Lith-O-Asp group, it was significantly lower at 2±4 nodules. Additionally, 4T1-Luc illumination signals, indicating tumor presence, were markedly stronger in the DMSO control group than in the Lith-O-Asp-treated group on days 7 and 9[1]. |
| Molecular Weight | 491.66 |
| Formula | C28H45NO6 |
| Cas No. | 881179-02-8 |
| Smiles | [H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@]4([H])C[C@@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)OC(=O)[C@@H](N)CC(O)=O)[C@H](C)CCC(O)=O |
| Relative Density. | 1.19 g/cm3 (Predicted) |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 106 mg/mL (215.6 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.